Search research articles
Contact Us
Filters
Showing results (11-20 of 24) with videos related to
Page
of 3
Sort By:
Journal of Biomolecular Screening
|
February 4, 2014
Fluorescence Lifetime-Based Competitive Binding Assays for Measuring the Binding Potency of Protease Inhibitors In Vitro
Andreas Boettcher, Nathalie Gradoux, Edwige Lorthiois, et al.
Psychopharmacology
|
July 18, 2009
Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect
Markus Fendt, Hugo Bürki, Stefan Imobersteg, et al.
Plos One
|
November 21, 2017
Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo
Ulf Guendisch, Jessica Weiss, Florence Ecoeur, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 3, 2011
Quinazolinedione sulfonamides: a novel class of competitive AMPA receptor antagonists with oral activity
Manuel Koller, Kurt Lingenhoehl, Markus Schmutz, et al.
Journal of Medicinal Chemistry
|
April 27, 2017
Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis
Juraj Velcicky, Wolfgang Miltz, Berndt Oberhauser, et al.
Chemmedchem
|
December 1, 2016
Synthesis and Biological Evaluation of New Triazolo- and Imidazolopyridine RORγt Inverse Agonists
Samuel Hintermann, Christine Guntermann, Henri Mattes, et al.
Chemmedchem
|
November 19, 2016
Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist
David Orain, Engin Tasdelen, Samuel Haessig, et al.
Chemmedchem
|
September 4, 2010
Design and synthesis of selective and potent orally active S1P5 agonists
Henri Mattes, Kumlesh Kumar Dev, Rochdi Bouhelal, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 27, 2011
6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists
David Orain, Silvio Ofner, Manuel Koller, et al.
Journal of Medicinal Chemistry
|
July 11, 2018
Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model
David A Carcache, Anna Vulpetti, Joerg Kallen, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 24) with videos related to
Sort By:
Page
of 3
Journal of Biomolecular Screening
|
February 4, 2014
Fluorescence Lifetime-Based Competitive Binding Assays for Measuring the Binding Potency of Protease Inhibitors In Vitro
Andreas Boettcher, Nathalie Gradoux, Edwige Lorthiois, et al.
Psychopharmacology
|
July 18, 2009
Fear-reducing effects of intra-amygdala neuropeptide Y infusion in animal models of conditioned fear: an NPY Y1 receptor independent effect
Markus Fendt, Hugo Bürki, Stefan Imobersteg, et al.
Plos One
|
November 21, 2017
Pharmacological inhibition of RORγt suppresses the Th17 pathway and alleviates arthritis in vivo
Ulf Guendisch, Jessica Weiss, Florence Ecoeur, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 3, 2011
Quinazolinedione sulfonamides: a novel class of competitive AMPA receptor antagonists with oral activity
Manuel Koller, Kurt Lingenhoehl, Markus Schmutz, et al.
Journal of Medicinal Chemistry
|
April 27, 2017
Development of Selective, Orally Active GPR4 Antagonists with Modulatory Effects on Nociception, Inflammation, and Angiogenesis
Juraj Velcicky, Wolfgang Miltz, Berndt Oberhauser, et al.
Chemmedchem
|
December 1, 2016
Synthesis and Biological Evaluation of New Triazolo- and Imidazolopyridine RORγt Inverse Agonists
Samuel Hintermann, Christine Guntermann, Henri Mattes, et al.
Chemmedchem
|
November 19, 2016
Design and Synthesis of Selurampanel, a Novel Orally Active and Competitive AMPA Receptor Antagonist
David Orain, Engin Tasdelen, Samuel Haessig, et al.
Chemmedchem
|
September 4, 2010
Design and synthesis of selective and potent orally active S1P5 agonists
Henri Mattes, Kumlesh Kumar Dev, Rochdi Bouhelal, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 27, 2011
6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists
David Orain, Silvio Ofner, Manuel Koller, et al.
Journal of Medicinal Chemistry
|
July 11, 2018
Optimizing a Weakly Binding Fragment into a Potent RORγt Inverse Agonist with Efficacy in an in Vivo Inflammation Model
David A Carcache, Anna Vulpetti, Joerg Kallen, et al.
Page
of 3